NASDAQ:OHRP - OHR Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2084 +0.01 (+5.04 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$0.2084
Today's Range$0.1925 - $0.2195
52-Week Range$0.18 - $2.18
Volume407,269 shs
Average Volume1.67 million shs
Market Capitalization$10.82 million
P/E Ratio-0.39
Dividend YieldN/A
Beta0.14

About OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical logoOHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Receive OHRP News and Ratings via Email

Sign-up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OHRP
CUSIPN/A
Phone212-682-8452

Debt

Debt-to-Equity RatioN/A
Current Ratio3.37
Quick Ratio3.37

Price-To-Earnings

Trailing P/E Ratio-0.39
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book0.67

Profitability

EPS (Most Recent Fiscal Year)($0.53)
Net Income$-23,810,000.00
Net MarginsN/A
Return on Equity-72.65%
Return on Assets-61.31%

Miscellaneous

Employees4
Outstanding Shares56,470,000

OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions

What is OHR Pharmaceutical's stock symbol?

OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) posted its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. View OHR Pharmaceutical's Earnings History.

What price target have analysts set for OHRP?

2 analysts have issued 1 year target prices for OHR Pharmaceutical's shares. Their predictions range from $7.00 to $10.00. On average, they expect OHR Pharmaceutical's stock price to reach $8.50 in the next year. View Analyst Ratings for OHR Pharmaceutical.

Are investors shorting OHR Pharmaceutical?

OHR Pharmaceutical saw a drop in short interest in April. As of April 13th, there was short interest totalling 1,963,843 shares, a drop of 30.7% from the March 30th total of 2,831,929 shares. Based on an average trading volume of 674,368 shares, the short-interest ratio is currently 2.9 days. Approximately 3.7% of the shares of the company are short sold.

Who are some of OHR Pharmaceutical's key competitors?

Who are OHR Pharmaceutical's key executives?

OHR Pharmaceutical's management team includes the folowing people:
  • Dr. Jason Scott Slakter, CEO, Pres & Director (Age 60)
  • Mr. Samuel Backenroth, Chief Financial Officer and VP of Bus. Devel. (Age 34)
  • Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 54)
  • Dr. Peter K. Kaiser M.D., Head of Product Devel.
  • Dr. Marlene Modi Ph.D., Head of Preclinical and Regulatory Affairs

Has OHR Pharmaceutical been receiving favorable news coverage?

News stories about OHRP stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OHR Pharmaceutical earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of OHR Pharmaceutical?

Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OHR Pharmaceutical's stock price today?

One share of OHRP stock can currently be purchased for approximately $0.2084.

How big of a company is OHR Pharmaceutical?

OHR Pharmaceutical has a market capitalization of $10.82 million. The biotechnology company earns $-23,810,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. OHR Pharmaceutical employs 4 workers across the globe.

How can I contact OHR Pharmaceutical?

OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]


MarketBeat Community Rating for OHR Pharmaceutical (OHRP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OHR Pharmaceutical (NASDAQ:OHRP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for OHR Pharmaceutical in the last 12 months. Their average twelve-month price target is $8.50, suggesting that the stock has a possible upside of 3,978.69%. The high price target for OHRP is $10.00 and the low price target for OHRP is $7.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.503.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.50$8.50$8.50$10.00
Price Target Upside: 3,978.69% upside320.79% upside320.79% upside1,539.34% upside

OHR Pharmaceutical (NASDAQ:OHRP) Consensus Price Target History

Price Target History for OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical (NASDAQ:OHRP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018Roth CapitalDowngradeBuy ➝ Neutral$7.00HighView Rating Details
8/16/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

OHR Pharmaceutical (NASDAQ:OHRP) Earnings History and Estimates Chart

Earnings by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical (NASDAQ OHRP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q2 2018($0.07)($0.05)ViewN/AView Earnings Details
2/15/2018Q1 2018($0.07)($0.07)ViewN/AView Earnings Details
12/15/2017Q4 2017($0.08)($0.08)ViewN/AView Earnings Details
8/8/2017Q3 2017($0.25)($0.07)ViewListenView Earnings Details
5/11/2017Q2 2017($0.30)($0.21)ViewN/AView Earnings Details
2/14/2017Q117($0.19)($0.21)ViewListenView Earnings Details
12/22/2016Q4 2016($0.24)($0.21)ViewN/AView Earnings Details
8/9/2016Q3 2016($0.23)($0.24)ViewN/AView Earnings Details
5/10/2016Q2($0.18)($0.17)ViewListenView Earnings Details
2/9/2016Q1 2016($0.24)($0.20)ViewN/AView Earnings Details
12/10/2015Q415($0.20)($0.13)ViewListenView Earnings Details
8/6/2015Q3 2015($0.21)($0.11)ViewN/AView Earnings Details
5/11/2015Q215($0.17)($0.12)ViewListenView Earnings Details
2/9/2015Q115($0.20)($0.18)ViewN/AView Earnings Details
12/22/2014($0.10)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OHR Pharmaceutical (NASDAQ:OHRP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OHR Pharmaceutical (NASDAQ OHRP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 9.15%
Insider Trading History for OHR Pharmaceutical (NASDAQ:OHRP)
Institutional Ownership by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical (NASDAQ OHRP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2017Orin HirschmanDirectorBuy142,858$0.70$100,000.60View SEC Filing  
4/10/2017Samuel BackenrothCFOBuy71,429$0.70$50,000.30212,596View SEC Filing  
6/20/2016Jason Scott SlakterCEOBuy8,786$2.85$25,040.10917,954View SEC Filing  
6/20/2016Samuel BackenrothCFOBuy2,468$2.84$7,009.12138,709View SEC Filing  
5/25/2016Jason Scott SlakterCEOBuy3,682$3.11$11,451.02913,072View SEC Filing  
5/24/2016Jason Scott SlakterCEOBuy28,068$3.15$88,414.20885,841View SEC Filing  
5/23/2016Samuel BackenrothCFOBuy2,500$3.17$7,925.00136,362View SEC Filing  
4/11/2016Jason Scott SlakterCEOBuy6,250$3.35$20,937.50884,504View SEC Filing  
3/7/2016Jason Scott SlakterCEOBuy6,250$3.63$22,687.50873,527View SEC Filing  
2/22/2016Jason Scott SlakterCEOBuy6,250$3.11$19,437.50865,854View SEC Filing  
1/19/2016Jason Scott SlakterCEOBuy6,250$3.62$22,625.00865,754View SEC Filing  
12/7/2015Jason Scott SlakterCEOBuy3,000$4.07$12,210.00509,146View SEC Filing  
11/3/2015Jason Scott SlakterCEOBuy13,350$3.00$40,050.0077,923View SEC Filing  
2/6/2015Irach B TaraporewalaCEOBuy3,705$6.75$25,008.75View SEC Filing  
2/6/2015June Sherie AlmenoffDirectorBuy6,000$6.75$40,500.00View SEC Filing  
2/6/2015Samuel BackenrothCFOBuy1,500$6.75$10,125.00View SEC Filing  
9/3/2014June Sherie AlmenoffDirectorBuy2,200$8.08$17,776.00View SEC Filing  
7/2/2014Ira A GreensteinDirectorBuy1,000$8.40$8,400.00View SEC Filing  
6/26/2014June Sherie AlmenoffDirectorBuy3,200$8.34$26,688.00View SEC Filing  
6/25/2014Thomas M RiedhammerDirectorBuy6,900$7.39$50,991.00View SEC Filing  
4/9/2014Ira A GreensteinDirectorBuy2,500$10.20$25,500.00View SEC Filing  
4/8/2014June Sherie AlmenoffDirectorBuy5,500$10.25$56,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OHR Pharmaceutical (NASDAQ OHRP) News Headlines

Source:
DateHeadline
OHR: Fiscal 2Q Earnings SnapshotOHR: Fiscal 2Q Earnings Snapshot
www.cnbc.com - May 16 at 5:49 PM
OHR Pharmaceutical (OHRP) Issues Quarterly  Earnings Results, Beats Expectations By $0.02 EPSOHR Pharmaceutical (OHRP) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 16 at 11:22 AM
Ohr Pharmaceutical Reports Fiscal Second Quarter 2018 Financial ResultsOhr Pharmaceutical Reports Fiscal Second Quarter 2018 Financial Results
finance.yahoo.com - May 15 at 5:52 PM
Stock Performance Review on Biotech Industry -- Neptune Technologies & Bioressources, NewLink Genetics, OHR Pharma, and OmerosStock Performance Review on Biotech Industry -- Neptune Technologies & Bioressources, NewLink Genetics, OHR Pharma, and Omeros
www.bizjournals.com - May 8 at 8:12 AM
OHR Pharmaceutical (OHRP) versus Progenics Pharmaceuticals (PGNX) Critical AnalysisOHR Pharmaceutical (OHRP) versus Progenics Pharmaceuticals (PGNX) Critical Analysis
www.americanbankingnews.com - May 3 at 5:54 AM
ValuEngine Upgrades OHR Pharmaceutical (OHRP) to "Hold"ValuEngine Upgrades OHR Pharmaceutical (OHRP) to "Hold"
www.americanbankingnews.com - May 2 at 11:06 PM
MAY 7 DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of an Expanded Lead Plaintiff Deadline in its Action to Recover Losses Suffered by Ohr Pharmaceutical, Inc. InvestorsMAY 7 DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of an Expanded Lead Plaintiff Deadline in its Action to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors
finance.yahoo.com - May 1 at 5:21 PM
OHR Pharmaceutical Inc (OHRP) Sees Significant Drop in Short InterestOHR Pharmaceutical Inc (OHRP) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 29 at 3:12 AM
Zacks Investment Research Upgrades OHR Pharmaceutical (OHRP) to BuyZacks Investment Research Upgrades OHR Pharmaceutical (OHRP) to Buy
www.americanbankingnews.com - April 17 at 8:43 PM
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact The FirmFINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact The Firm
finance.yahoo.com - April 9 at 5:26 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRPINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRP
finance.yahoo.com - April 9 at 5:26 PM
OHR Pharmaceutical (OHRP) Upgraded to Buy by Zacks Investment ResearchOHR Pharmaceutical (OHRP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - April 6 at 8:19 AM
OHR Pharmaceutical (OHRP) Upgraded at Zacks Investment ResearchOHR Pharmaceutical (OHRP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 5 at 5:46 PM
OHR Pharmaceutical (OHRP) Cut to "Hold" at Zacks Investment ResearchOHR Pharmaceutical (OHRP) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 11:26 PM
OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ...OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ...
globenewswire.com - March 27 at 5:18 PM
OHRP EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018OHRP EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 26 at 5:23 PM
OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ohr Pharmaceutical, Inc. To Contact The FirmOHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ohr Pharmaceutical, Inc. To Contact The Firm
finance.yahoo.com - March 26 at 5:23 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr ... - Business Wire (press release)EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr ... - Business Wire (press release)
www.businesswire.com - March 21 at 8:41 AM
The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc ... - Business Wire (press release)The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc ... - Business Wire (press release)
www.businesswire.com - March 21 at 8:41 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 20 at 5:21 PM
The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018 (OHRP)The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Ohr Pharmaceutical, Inc. Shareholders and a Lead Plaintiff Deadline of April 16, 2018 (OHRP)
finance.yahoo.com - March 19 at 5:21 PM
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Ohr Pharmaceutical, Inc. to Contact the FirmDEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Ohr Pharmaceutical, Inc. to Contact the Firm
finance.yahoo.com - March 16 at 6:33 PM
Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical OfficerInnovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer
finance.yahoo.com - March 13 at 8:18 AM
Short Interest in OHR Pharmaceutical Inc (OHRP) Drops By 27.7%Short Interest in OHR Pharmaceutical Inc (OHRP) Drops By 27.7%
www.americanbankingnews.com - March 12 at 2:14 AM
OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ... - Business Wire (press release)OHR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ... - Business Wire (press release)
www.businesswire.com - March 9 at 8:14 AM
The Klein Law Firm Announces a Class Action Filed on Behalf of ... - GlobeNewswire (press release)The Klein Law Firm Announces a Class Action Filed on Behalf of ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:14 AM
OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies ... - Business Wire (press release)OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies ... - Business Wire (press release)
www.businesswire.com - March 8 at 8:17 AM
OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018OHRP INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 7 at 6:39 PM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - March 7 at 6:39 PM
OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class ... - GlobeNewswire (press release)OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class ... - GlobeNewswire (press release)
globenewswire.com - March 2 at 8:12 AM
OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Ohr Pharmaceutical, Inc. and a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - March 1 at 5:55 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018
finance.yahoo.com - February 28 at 6:07 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - February 27 at 5:58 PM
The Klein Law Firm Reminds Investors of an Investigation Regarding Possible Violations of Federal Securities Laws by Ohr Pharmaceutical, Inc.The Klein Law Firm Reminds Investors of an Investigation Regarding Possible Violations of Federal Securities Laws by Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 23 at 6:02 PM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ohr Pharmaceutical, Inc. (OHRP)The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Ohr Pharmaceutical, Inc. (OHRP)
finance.yahoo.com - February 20 at 5:50 PM
Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - February 18 at 8:14 AM
Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - February 17 at 8:11 AM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Ohr Pharmaceutical, Inc.Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 15 at 5:23 PM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - February 15 at 5:23 PM
OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ohr Pharmaceutical, Inc.OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 15 at 5:23 PM
OHR Pharmaceutical (OHRP) Announces  Earnings Results, Meets EstimatesOHR Pharmaceutical (OHRP) Announces Earnings Results, Meets Estimates
www.americanbankingnews.com - February 15 at 10:08 AM
Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial ResultsOhr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
finance.yahoo.com - February 15 at 9:25 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRPSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRP
finance.yahoo.com - February 14 at 3:43 PM
Who Are The Major Shareholders Of OHR Pharmaceutical Inc (NASDAQ:OHRP)?Who Are The Major Shareholders Of OHR Pharmaceutical Inc (NASDAQ:OHRP)?
finance.yahoo.com - February 12 at 9:18 AM
OHR Pharmaceutical (OHRP) Scheduled to Post Quarterly Earnings on MondayOHR Pharmaceutical (OHRP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 5 at 4:16 AM
OHR Pharmaceutical (OHRP) Stock Rating Upgraded by ValuEngineOHR Pharmaceutical (OHRP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 7:10 PM
OHR Pharmaceutical Inc (OHRP) Short Interest Up 47.8% in JanuaryOHR Pharmaceutical Inc (OHRP) Short Interest Up 47.8% in January
www.americanbankingnews.com - January 28 at 1:08 AM
Head to Head Contrast: ImmunoGen (IMGN) vs. Ohr Pharmaceuticals (OHRP)Head to Head Contrast: ImmunoGen (IMGN) vs. Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - January 9 at 9:38 AM
Zacks: Ohr Pharmaceuticals, Inc. (OHRP) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Ohr Pharmaceuticals, Inc. (OHRP) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 6 at 5:18 AM

SEC Filings

OHR Pharmaceutical (NASDAQ:OHRP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OHR Pharmaceutical (NASDAQ:OHRP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OHR Pharmaceutical (NASDAQ OHRP) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.